Home
The Department of Biomedicine

News archive for The Department of Biomedicine

Tore Ivar Malmei Aarsland will defend his PhD degree at the University of Bergen on 21 May 2024 with the thesis "Tryptophan and kynurenine pathway metabolites in neuropsychiatric disorders".
Brain calcification can cause movement disorders and cognitive impairment. New research by the Arnesen Lab at UiB provides increased insight into how these calcifications occur.
Congratulations to Peter on becoming a PhD holder!
Peter Daniel Szigetvari will defend his PhD degree at the University of Bergen on 14 February 2024 with the thesis "Monoamine synthesis in neurometabolic disorders affecting catecholaminergic functioning".
The Brenk lab has published an article in which they have investigated the presence of metal-coordinating groups in screening libraries and chemical spaces. This can help with the discovery for new inhibitors for metallo enzymes.
Researchers from the University of Bergen (UiB) have uncovered that proteins use a common chemical label as a shield to protect them from degradation, which in turn affects motility and aging.
Research advisors at the Faculty of Medicine have recently launched a new portal for researchers applying for external funding.
We congratulate Marianne Hjellvik Hannisdal for this accolade, winning best poster prize at the medical faculty‘s research day, with over 30 talented phd fellows who presented their excellent research projects in the form of poster presentations!
On Tuesday August 15th, Devaki defended her PhD at the University of Oulu. The opponent was Associate Professor Beáta Bugyi from the University of Pécs Medical School, Pécs, Hungary. We all very much enjoyed an insightful discussion on actins, actin depolymerizing factors, and their roles in the malaria parasite. Thanks to everyone involved and huge congratulations to Dr. Devaki Lasiwa!
The impact of the most common protein modification, N-terminal acetylation, has remained a conundrum in the field since its very origin. A new UiB article adds a piece to this puzzle.
As part of a consortium lead by the EU-Openscreen head office with the overall goal to improve the services offered by EU-Openscreen, the Brenk group has got funding to work on Ribotacs. Ribotacs are small molecules that selectively bind RNAs and a RNAse and thus lead targeted RNA degradation. We look forward to a succesfull collaboration.
This month, Dr. Stanley Makumire joined our group as a post-doctoral fellow. We look forward to working together in the coming years!
In March, we had a Drug Discovery meeting to showcase the research that is going on Bergen and to connect the groups active in this area. Nearly 50 people had signed up of the meeting and we had 9 different talks covering topics from target discovery all the way to clinical trials.
The second excellent news of the day was that Jane and Aatos Erkko foundation in Finland has decided to support our work with a whole 842000 € in the next three years. This decision could not have been more welcome and secures the continuation of our work. I am utmost grateful to Jane and Aatos Erkko foundation and extremely relieved. I hope one day also Norwegian funding bodies will see some... Read more
Today brought some pretty awesome news. The first came in the wee hours, telling that Henni's collaborative paper with Maddy Dans from the lab of Paul Gilson from the Burnet Institute (and a number of other collaborators) was accepted for publication in PLoS Biology. Looking forward to see this great story on inhibitors of the malaria profilactin complex finally out soon! Many thanks and huge... Read more

Pages